Q2 FY27 revenue up 25%; EBITDA margin 33%; Nueclear sale planned
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.7 pts more than Nifty Microcap 250 and 4.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Q2 FY27 revenue rose 25% to INR271 crore; gross margin was 74.2%, EBITDA margin 33%, and PAT before exceptions INR60 crore, up 26%. It added five labs and 1,180 franchisees, reaching 12,911 active franchisees. It booked a non-cash INR45 crore impairment and seeks approval to sell Nueclear Healthcare for INR141 crore. It had INR211 crore net cash and no debt. Management anchors long-term EBITDA margin at 31% to 31.5% while funding growth.
Strong growth and no debt support the stock; the Nueclear exit may lift margins, while launch spending may weigh on near-term earnings.